お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ
株式会社グローバルインフォメーション
表紙:マイトジェン(分裂促進因子)活性化タンパク質キナーゼ3:パイプライン製品の分析
市場調査レポート
商品コード
365753

マイトジェン(分裂促進因子)活性化タンパク質キナーゼ3:パイプライン製品の分析

Mitogen Activated Protein Kinase 3 - Pipeline Review, H2 2019

出版日: | 発行: Global Markets Direct | ページ情報: 英文 64 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=109.72円
マイトジェン(分裂促進因子)活性化タンパク質キナーゼ3:パイプライン製品の分析
出版日: 2019年12月27日
発行: Global Markets Direct
ページ情報: 英文 64 Pages
納期: 即納可能 即納可能とは
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートでは、マイトジェン(分裂促進因子)活性化タンパク質キナーゼ3を標的とした治療薬開発パイプラインの現況と最新アップデートによる各開発段階の比較分析、企業や研究機関によって開発中の治療薬、治療薬の評価、後期段階および中止されたプロジェクトに関する情報などを最新のニュースや発表も交えて提供しています。

イントロダクション

  • 調査範囲

マイトジェン(分裂促進因子)活性化タンパク質キナーゼ3 概要

治療薬の開発

  • 開発中の製品:開発段階別
  • 開発中の製品:治療領域別
  • 開発中の製品:症状別

パイプライン製品の概況

  • 後期段階の製品
  • 初期段階の製品

企業で開発中の製品

治療薬の評価

  • 単剤/併用治療薬の場合
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

治療薬開発に従事している企業

  • AGV Discovery, SAS
  • Genentech, Inc.
  • Kura Oncology, Inc.
  • Laurent Pharmaceuticals Inc.
  • Merck & Co., Inc.
  • Merck KGaA

薬剤プロファイルs

休止中のプロジェクト

開発が中止された製品

主なニュースおよびプレスリリース

付録

図表

図表

List of Tables

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Indications, H2 2019
  • Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..2), H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Pipeline by Antengene Corp, H2 2019
  • Pipeline by Asana BioSciences LLC, H2 2019
  • Pipeline by Astex Pharmaceuticals Inc, H2 2019
  • Pipeline by BioMed Valley Discoveries Inc, H2 2019
  • Pipeline by Eli Lilly and Co, H2 2019
  • Pipeline by Kalyra Pharmaceuticals Inc, H2 2019
  • Pipeline by Kura Oncology Inc, H2 2019
  • Pipeline by Merck & Co Inc, H2 2019
  • Pipeline by Merck KGaA, H2 2019
  • Pipeline by Shanghai Green Valley Pharmaceutical Co Ltd, H2 2019
  • Dormant Projects, H2 2019
  • Discontinued Products, H2 2019

List of Figures

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Top 10 Indications, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Routes of Administration, H2 2019
  • Number of Products by Molecule Types, H2 2019
  • Number of Products by Stage and Molecule Types, H2 2019
目次
Product Code: GMDHC1991TDB

Summary

Mitogen Activated Protein Kinase 3 (ERT2 or Insulin Stimulated MAP2 Kinase or Extracellular Signal Regulated Kinase 1 or MAP Kinase Isoform p44 or Microtubule Associated Protein 2 Kinase or p44 ERK1 or MAPK3 or EC 2.7.11.24) - Mitogen-activated protein kinase 3 is an enzyme encoded by the MAPK3 gene. It acts in a signaling cascade that regulates various cellular processes such as proliferation, differentiation, and cell cycle progression in response to a variety of extracellular signals. It is activated by upstream kinases resulting in its translocation to the nucleus where it phosphorylates nuclear targets.

Mitogen Activated Protein Kinase 3 (ERT2 or Insulin Stimulated MAP2 Kinase or Extracellular Signal Regulated Kinase 1 or MAP Kinase Isoform p44 or Microtubule Associated Protein 2 Kinase or p44 ERK1 or MAPK3 or EC 2.7.11.24) pipeline Target constitutes close to 11 molecules. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 3, 5, 1 and 2 respectively. Report covers products from therapy areas Oncology, Immunology and Musculoskeletal Disorders which include indications Non-Small Cell Lung Cancer, Metastatic Colorectal Cancer, Metastatic Melanoma, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Esophageal Cancer, Melanoma, Solid Tumor, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Adenocarcinoma, Bile Duct Cancer (Cholangiocarcinoma), Chronic Lymphocytic Leukemia (CLL), Gastric Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Hepatocellular Carcinoma, Knee Osteoarthritis, Mantle Cell Lymphoma, Marginal Zone B-cell Lymphoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Pancreatic Cancer, Metastatic Uveal Melanoma, Myelodysplastic Syndrome, Pancreatic Cancer, Psoriasis, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Renal Cell Carcinoma and Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma).

The latest report Mitogen Activated Protein Kinase 3 - Pipeline Review, H2 2019, outlays comprehensive information on the Mitogen Activated Protein Kinase 3 (ERT2 or Insulin Stimulated MAP2 Kinase or Extracellular Signal Regulated Kinase 1 or MAP Kinase Isoform p44 or Microtubule Associated Protein 2 Kinase or p44 ERK1 or MAPK3 or EC 2.7.11.24) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Mitogen Activated Protein Kinase 3 (ERT2 or Insulin Stimulated MAP2 Kinase or Extracellular Signal Regulated Kinase 1 or MAP Kinase Isoform p44 or Microtubule Associated Protein 2 Kinase or p44 ERK1 or MAPK3 or EC 2.7.11.24) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Mitogen Activated Protein Kinase 3 (ERT2 or Insulin Stimulated MAP2 Kinase or Extracellular Signal Regulated Kinase 1 or MAP Kinase Isoform p44 or Microtubule Associated Protein 2 Kinase or p44 ERK1 or MAPK3 or EC 2.7.11.24)
  • The report reviews Mitogen Activated Protein Kinase 3 (ERT2 or Insulin Stimulated MAP2 Kinase or Extracellular Signal Regulated Kinase 1 or MAP Kinase Isoform p44 or Microtubule Associated Protein 2 Kinase or p44 ERK1 or MAPK3 or EC 2.7.11.24) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Mitogen Activated Protein Kinase 3 (ERT2 or Insulin Stimulated MAP2 Kinase or Extracellular Signal Regulated Kinase 1 or MAP Kinase Isoform p44 or Microtubule Associated Protein 2 Kinase or p44 ERK1 or MAPK3 or EC 2.7.11.24) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Mitogen Activated Protein Kinase 3 (ERT2 or Insulin Stimulated MAP2 Kinase or Extracellular Signal Regulated Kinase 1 or MAP Kinase Isoform p44 or Microtubule Associated Protein 2 Kinase or p44 ERK1 or MAPK3 or EC 2.7.11.24) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Mitogen Activated Protein Kinase 3 (ERT2 or Insulin Stimulated MAP2 Kinase or Extracellular Signal Regulated Kinase 1 or MAP Kinase Isoform p44 or Microtubule Associated Protein 2 Kinase or p44 ERK1 or MAPK3 or EC 2.7.11.24) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Mitogen Activated Protein Kinase 3 (ERT2 or Insulin Stimulated MAP2 Kinase or Extracellular Signal Regulated Kinase 1 or MAP Kinase Isoform p44 or Microtubule Associated Protein 2 Kinase or p44 ERK1 or MAPK3 or EC 2.7.11.24)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Mitogen Activated Protein Kinase 3 (ERT2 or Insulin Stimulated MAP2 Kinase or Extracellular Signal Regulated Kinase 1 or MAP Kinase Isoform p44 or Microtubule Associated Protein 2 Kinase or p44 ERK1 or MAPK3 or EC 2.7.11.24) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Mitogen Activated Protein Kinase 3 (ERT2 or Insulin Stimulated MAP2 Kinase or Extracellular Signal Regulated Kinase 1 or MAP Kinase Isoform p44 or Microtubule Associated Protein 2 Kinase or p44 ERK1 or MAPK3 or EC 2.7.11.24) - Overview
  • Mitogen Activated Protein Kinase 3 (ERT2 or Insulin Stimulated MAP2 Kinase or Extracellular Signal Regulated Kinase 1 or MAP Kinase Isoform p44 or Microtubule Associated Protein 2 Kinase or p44 ERK1 or MAPK3 or EC 2.7.11.24) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Mitogen Activated Protein Kinase 3 (ERT2 or Insulin Stimulated MAP2 Kinase or Extracellular Signal Regulated Kinase 1 or MAP Kinase Isoform p44 or Microtubule Associated Protein 2 Kinase or p44 ERK1 or MAPK3 or EC 2.7.11.24) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Mitogen Activated Protein Kinase 3 (ERT2 or Insulin Stimulated MAP2 Kinase or Extracellular Signal Regulated Kinase 1 or MAP Kinase Isoform p44 or Microtubule Associated Protein 2 Kinase or p44 ERK1 or MAPK3 or EC 2.7.11.24) - Companies Involved in Therapeutics Development
  • Antengene Corp
  • Asana BioSciences LLC
  • Astex Pharmaceuticals Inc
  • BioMed Valley Discoveries Inc
  • Eli Lilly and Co
  • Kalyra Pharmaceuticals Inc
  • Kura Oncology Inc
  • Merck & Co Inc
  • Merck KGaA
  • Shanghai Green Valley Pharmaceutical Co Ltd
  • Mitogen Activated Protein Kinase 3 (ERT2 or Insulin Stimulated MAP2 Kinase or Extracellular Signal Regulated Kinase 1 or MAP Kinase Isoform p44 or Microtubule Associated Protein 2 Kinase or p44 ERK1 or MAPK3 or EC 2.7.11.24) - Drug Profiles
  • ASN-007 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ASTX-029 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ATG-017 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • JSI-287 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • KO-947 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • LY-3214996 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • MK-8353 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit ERK1 and ERK2 for Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit ERK1 and ERK2 for Pancreatic Ductal Adenocarcinoma - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • sprifermin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ulixertinib - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Mitogen Activated Protein Kinase 3 (ERT2 or Insulin Stimulated MAP2 Kinase or Extracellular Signal Regulated Kinase 1 or MAP Kinase Isoform p44 or Microtubule Associated Protein 2 Kinase or p44 ERK1 or MAPK3 or EC 2.7.11.24) - Dormant Products
  • Mitogen Activated Protein Kinase 3 (ERT2 or Insulin Stimulated MAP2 Kinase or Extracellular Signal Regulated Kinase 1 or MAP Kinase Isoform p44 or Microtubule Associated Protein 2 Kinase or p44 ERK1 or MAPK3 or EC 2.7.11.24) - Discontinued Products
  • Mitogen Activated Protein Kinase 3 (ERT2 or Insulin Stimulated MAP2 Kinase or Extracellular Signal Regulated Kinase 1 or MAP Kinase Isoform p44 or Microtubule Associated Protein 2 Kinase or p44 ERK1 or MAPK3 or EC 2.7.11.24) - Product Development Milestones
  • Featured News & Press Releases
  • Oct 24, 2019: Asana BioSciences to present phase 1 clinical safety and efficacy data of oral, once-weekly, ASN007, a novel ERK 1/2 inhibitor, at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
  • Oct 08, 2019: EMD Serono Announces JAMA Publication of Phase II Results of Sprifermin for Osteoarthritis Structure Modification
  • May 15, 2019: Eli Lilly presents update on ERK inhibitor, LY3214996 at ASCO 2019
  • Apr 17, 2018: Merck to Present on Sprifermin at OARSI 2018 World Congress
  • Apr 10, 2018: Asana BioSciences Announces Presentations of ASN007 (ERK1/2 inhibitor) at the American Association for Cancer Research Annual Meeting
  • Apr 09, 2018: Kura Oncology Presents Poster on KO-947 at AACR Annual Meeting 2018
  • Feb 22, 2018: Phase I Clinical Trial Shows Promise as Investigational Drug for Melanoma
  • Jan 03, 2018: Asana BioSciences Announces Acceptance of IND Application for Its Oral ERK1/2 Inhibitor
  • Dec 15, 2017: First-in-class ERK1/2 Inhibitor Safe, Shows Early Efficacy in Patients With Advanced Solid Tumors
  • Nov 04, 2017: Merck KGaA, Darmstadt, Germany Presents Late Breaking Clinical Data from Phase II Trial of Sprifermin for Osteoarthritis Disease Modification
  • Oct 24, 2017: Asana BioSciences to Present Update On Lead Molecule ASN-007 at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
  • Oct 20, 2017: Merck Presents New Data on Sprifermin at 2017 ACR/ARHP Annual Meeting
  • Oct 03, 2017: First-in-class ERK inhibitor ulixertinib (BVD-523) shows promise in preclinical cancer models
  • Jun 21, 2017: NovellusDx Announced the Completion of the First Phase of an In-vitro Study of BioMed Valley Discoveries' BVD523
  • May 26, 2017: BioMed Valley Discoveries announces presentation of early clinical activity of first-in-class cancer therapy ulixertinib at 2017 ASCO annual meeting
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.